SEC Comment Letter for Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Jul 14, 2023
Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: July 14, 2023 · CIK: 0001512762 · Accession: 0000000000-23-007521
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273179
Letter
United States securities and exchange commission logo July 13, 2023 McDavid Stilwell Chief Financial Officer Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 Re:Coherus BioSciences, Inc. Registration Statement on Form S-4 Filed July 7, 2023 File No. 333-273179 Dear McDavid Stilwell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Phillip S. Stoup
Show Raw Text
United States securities and exchange commission logo
July 13, 2023
McDavid Stilwell
Chief Financial Officer
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
Re:Coherus BioSciences, Inc.
Registration Statement on Form S-4
Filed July 7, 2023
File No. 333-273179
Dear McDavid Stilwell:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Phillip S. Stoup